CytoMed Therapeutics Limited Ordinary Shares
GDTCCytoMed Therapeutics Limited is a biotechnology company focused on the development of cell-based immunotherapies for cancer treatment. The company specializes in innovative therapeutic platforms aimed at enhancing immune responses against tumors, with a focus on unmet medical needs in oncology.
Company News
CytoMed Therapeutics has completed the acquisition of allogeneic gamma delta T cell technology from TC BioPharm, aiming to develop cancer treatments for China and India. The technology has completed a Phase I clinical trial and received FDA orphan drug designation for Acute Myeloid Leukemia.
The 73rd Emerging Growth Conference is scheduled for July 17-18, 2024, featuring presentations from various companies in the healthcare, technology, and energy sectors.
